Albendazole sensitizes cancer cells to ionizing radiation

Radiation Oncology

Volumn 6, Issue 1, 2011, Pages

  Patel, Kirtesh ^a   Doudican, Nicole A ^a   Schiff, Peter B ^a,b   Orlow, Seth J ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY   (United States)

Author keywords

Albendazole; Apoptosis; Dna damage; Ionizing radiation; Microtubules

Indexed keywords

ALBENDAZOLE; HISTONE H2AX; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; ANTINEOPLASTIC AGENT; RADIOSENSITIZING AGENT;

ARTICLE; CANCER CELL; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; DNA DAMAGE; HUMAN; IONIZING RADIATION; LUNG SMALL CELL CANCER; MELANOMA; PROTEIN PHOSPHORYLATION; APOPTOSIS; BRAIN TUMOR; CELL CYCLE; CELL PROLIFERATION; DRUG EFFECT; LUNG TUMOR; METASTASIS; PATHOLOGY; SKIN TUMOR; TUMOR CELL LINE; WESTERN BLOTTING;

ALBENDAZOLE; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; LUNG NEOPLASMS; MELANOMA; RADIATION-SENSITIZING AGENTS; SKIN NEOPLASMS; SMALL CELL LUNG CARCINOMA;

EID: 81155127527     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-6-160     Document Type: Article

References (22)

1. Johnson JD, Young B. Demographics of brain metastasis. Neurosurg Clin N Am 1996, 7(3):337-44.
2. Auperin A, Arriagada R, Pignon JP, Le Pechoux C, Gregor A, Stephens RJ, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 1999, 341(7):476-84. 10.1056/NEJM199908123410703, 10441603.
3. Margolin K, Atkins B, Thompson A, Ernstoff S, Weber J, Flaherty L, et al. Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group. J Cancer Res Clin Oncol 2002, 128(4):214-8. 10.1007/s00432-002-0323-8, 11935312.
4. Hofmann M, Kiecker F, Wurm R, Schlenger L, Budach V, Sterry W, et al. Temozolomide with or without radiotherapy in melanoma with unresectable brain metastases. J Neurooncol 2006, 76(1):59-64. 10.1007/s11060-005-2914-0, 16132502.
5. Doudican N, Rodriguez A, Osman I, Orlow SJ. Mebendazole induces apoptosis via Bcl-2 inactivation in chemoresistant melanoma cells. Mol Cancer Res 2008, 6(8):1308-15. 10.1158/1541-7786.MCR-07-2159, 18667591.
6. Jung H, Hurtado M, Sanchez M, Medina MT, Sotelo J. Plasma and CSF levels of albendazole and praziquantel in patients with neurocysticercosis. Clin Neuropharmacol 1990, 13(6):559-64. 10.1097/00002826-199012000-00008, 2276121.
7. Canestraro M, Galimberti S, Savli H, Palumbo GA, Tibullo D, Nagy B, et al. Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from patients affected by myeloproliferative disorders. Cancer Genet Cytogenet 2010, 199(2):110-20. 10.1016/j.cancergencyto.2010.02.010, 20471514.
8. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984, 22:27-55.
9. Zaharevitz DW, Holbeck SL, Bowerman C, Svetlik PA. COMPARE: a web accessible tool for investigating mechanisms of cell growth inhibition. J Mol Graph Model 2002, 20(4):297-303. 10.1016/S1093-3263(01)00126-7, 11858638.
10. Gupta RS. Cross-resistance of nocodazole-resistant mutants of CHO cells toward other microtubule inhibitors: similar mode of action of benzimidazole carbamate derivatives and NSC 181928 and TN-16. Mol Pharmacol 1986, 30(2):142-8.
11. Lacey E, Brady RL, Prichard RK, Watson TR. Comparison of inhibition of polymerisation of mammalian tubulin and helminth ovicidal activity by benzimidazole carbamates. Vet Parasitol 1987, 23(1-2):105-19. 10.1016/0304-4017(87)90029-X, 3564338.
12. Cai ZY, Galettis P, Lu Y, Morris DL, Pourgholami MH. Pharmacokinetics of albendazole in New Zealand white rabbits: oral versus intraperitoneal administration. Anticancer Res 2007, 27(1A):417-22.
13. Pourgholami MH, Woon L, Almajd R, Akhter J, Bowery P, Morris DL. In vitro and in vivo suppression of growth of hepatocellular carcinoma cells by albendazole. Cancer Lett 2001, 165(1):43-9. 10.1016/S0304-3835(01)00382-2, 11248417.
14. Rades D, Heisterkamp C, Huttenlocher S, Bohlen G, Dunst J, Haatanen T, et al. Dose escalation of whole-brain radiotherapy for brain metastases from melanoma. Int J Radiat Oncol Biol Phys 2010, 77(2):537-41. 10.1016/j.ijrobp.2009.05.001, 19733017.
15. Pourgholami MH, Szwajcer M, Chin M, Liauw W, Seef J, Galettis P, et al. Phase I clinical trial to determine maximum tolerated dose of oral albendazole in patients with advanced cancer. Cancer Chemother Pharmacol 2010, 65(3):597-605. 10.1007/s00280-009-1157-8, 19904538.
16. Sonnichsen DS, Relling MV. Clinical pharmacokinetics of paclitaxel. Clin Pharmacokinet 1994, 27(4):256-69. 10.2165/00003088-199427040-00002, 7834963.
17. Haldar S, Jena N, Croce CM. Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci USA 1995, 92(10):4507-11. PMCID: 41973, 10.1073/pnas.92.10.4507, 41973, 7753834.
18. Geard CR, Jones JM, Schiff PB. Taxol and radiation. J Natl Cancer Inst Monogr 1993, (15):89-94.
19. Sasaki YF, Saga A, Akasaka M, Yoshida K, Nishidate E, Su YQ, et al. In vivo genotoxicity of ortho-phenylphenol, biphenyl, and thiabendazole detected in multiple mouse organs by the alkaline single cell gel electrophoresis assay. Mutat Res 1997, 395(2-3):189-98.
20. Nianjun H, Cerepnalkoski L, Nwankwo JO, Dews M, Landolph JR. Induction of chromosomal aberrations, cytotoxicity, and morphological transformation in mammalian cells by the antiparasitic drug flubendazole and the antineoplastic drug harringtonine. Fundam Appl Toxicol 1994, 22(2):304-13. 10.1006/faat.1994.1034, 8005380.
21. Chu SW, Badar S, Morris DL, Pourgholami MH. Potent inhibition of tubulin polymerisation and proliferation of paclitaxel-resistant 1A9PTX22 human ovarian cancer cells by albendazole. Anticancer Res 2009, 29(10):3791-6.
22. Khalilzadeh A, Wangoo KT, Morris DL, Pourgholami MH. Epothilone-paclitaxel resistant leukemic cells CEM/dEpoB300 are sensitive to albendazole: Involvement of apoptotic pathways. Biochem Pharmacol 2007, 74(3):407-14. 10.1016/j.bcp.2007.05.006, 17560963.